HC Wainwright Issues Negative Outlook for FENC Earnings

Adherex Technologies Inc. (NASDAQ:FENC) – Research analysts at HC Wainwright decreased their Q3 2026 earnings estimates for shares of Adherex Technologies in a research report issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.12 per share for the quarter, down from their previous forecast of $0.19. The consensus estimate for Adherex Technologies’ current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Adherex Technologies’ Q4 2026 earnings at $0.16 EPS, Q3 2027 earnings at $0.26 EPS, Q4 2027 earnings at $0.30 EPS and FY2027 earnings at $0.96 EPS.

FENC has been the topic of several other research reports. Zacks Research cut Adherex Technologies from a “hold” rating to a “strong sell” rating in a research report on Wednesday, March 25th. Piper Sandler assumed coverage on shares of Adherex Technologies in a research note on Friday, January 9th. They issued an “overweight” rating and a $18.00 price target on the stock. B. Riley Financial started coverage on shares of Adherex Technologies in a research report on Thursday, February 12th. They set a “buy” rating and a $16.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adherex Technologies in a research note on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Adherex Technologies from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.25.

Adherex Technologies Trading Up 6.6%

NASDAQ:FENC opened at $6.15 on Tuesday. The stock has a 50 day simple moving average of $7.77 and a 200 day simple moving average of $8.04. The stock has a market cap of $211.99 million, a P/E ratio of -18.09 and a beta of 0.75. Adherex Technologies has a 1-year low of $4.68 and a 1-year high of $9.92.

Adherex Technologies (NASDAQ:FENC) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.21). The firm had revenue of $13.78 million for the quarter, compared to the consensus estimate of $14.75 million. Adherex Technologies had a negative return on equity of 183.18% and a negative net margin of 22.62%.

Insider Activity

In other news, Director Rosty Raykov sold 10,349 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $7.76, for a total transaction of $80,308.24. Following the completion of the transaction, the director owned 98,477 shares of the company’s stock, valued at approximately $764,181.52. The trade was a 9.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 10.98% of the company’s stock.

Institutional Trading of Adherex Technologies

A hedge fund recently bought a new stake in Adherex Technologies stock. Jane Street Group LLC acquired a new stake in Adherex Technologies Inc. (NASDAQ:FENC) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 14,718 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned 0.05% of Adherex Technologies at the end of the most recent reporting period. Institutional investors own 55.51% of the company’s stock.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.